No new drugs, just watching: melanoma patients monitored years after experimental combo

NCT ID NCT06848088

First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 29 times

Summary

This study checks on people with advanced melanoma who previously received a combination of two experimental drugs, fianlimab and cemiplimab. No new treatment is given; instead, researchers track their health, cancer status, and any side effects over time. The goal is to understand the long-term safety and effectiveness of the earlier therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • California Pacific Medical Center

    San Francisco, California, 94115, United States

  • Cancer & Hematology Centers of Western Michigan

    Grand Rapids, Michigan, 49546, United States

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • South Texas Oncology And Hematology

    San Antonio, Texas, 78229, United States

  • St. Vincent's University Hospital

    Dublin, D04 T6F4, Ireland

  • The Angeles Clinic and Research Institute - West Los Angeles Office

    Los Angeles, California, 90025, United States

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.